Login      Sign-Up  
Skip Navigation Links
Home
Laws
Bills
Sessions
House
Senate
Committees
Legislators
My Legis
2026 Regular Session
Other Sessions
Scroll up
Scroll down
2026 Regular Session
Other Sessions
Scroll up
Scroll down
House Committees
Senate Committees
Miscellaneous Committees
Scheduled Meetings
Scroll up
Scroll down
Representatives
Senators
Caucuses and Delegations
Scroll up
Scroll down
      RS 37:1226.1     

  

§1226.1. Communication to the prescriber

            A. No later than five business days following the dispensing of a biological product, the dispensing pharmacist or his designee shall communicate to the prescriber the specific product provided to the patient, including the name of the product and the manufacturer.

            B. The required communication included in Subsection A of this Section may be done by any means.

            C. No communication shall be required if there is no interchangeable or therapeutically equivalent biological product approved by the United States Food and Drug Administration for the product prescribed, or if the prescription is a refill not changed from the product dispensed on the prior filling of the prescription.

            D. Nothing in this Section shall create a cause of action against the prescriber and the dispensing pharmacist or his designee for a communication as required pursuant to this Section.

            E. No communication shall be required pursuant to this Section if the prescriber indicates "dispense as written".

            Acts 2015, No. 391, §1; Acts 2018, No. 206, §3.



If you experience any technical difficulties navigating this website, contact the webmaster.
P.O. Box 94062 (900 North Third Street) Baton Rouge, Louisiana 70804-9062